Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma

Author(s):
Apellaniz-Ruiz, M.; Diekstra, M.H.; Roldan, J.M.; ; Castellano, D.; Gelderblom, H.; Mathijssen, R.H.J.; Swen, J.J.; Bohringer, S.; Garcia-Donas, J.; Rini, B.I.; Guchelaar, H.J. (0000-0002-7085-1383); Rodriguez-Antona, C.
Published
2017
Publication type
Article / Letter to editor
advanced renal cell carcinomaKDRpolymorphismsunitinibvascular endothelial growth factor receptor 2
Date issued
2017-06-30
Language
English
Is part of
Pharmacogenetics and Genomics (2017), Vol. 27, no. 6, p. 227-231
hdl
1887/114721
doi
10.1097/FPC.0000000000000280